CompletedNCT00443391
A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)
Researchers studied ABT-089, tracking side effects to assess long-term safety and tolerability in adults with ADHD.
Medication studyAges 18–60United States
Understand this study
What did researchers investigate?
Researchers studied ABT-089, tracking side effects to assess long-term safety and tolerability in adults with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- Mesa and 20 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateFebruary 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 141
- Sponsor
- AbbVie (prior sponsor, Abbott)
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00443391
- Official title
Show the full official title
The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study
Recruitment & locations
CompletedMesa · Lafayette · San Diego
17 more locations
- Jacksonville
- Maitland
- Tampa
- Smyrna
- Newton
- Farmington Hills
- Omaha
- New York
- Chapel Hill
- Portland
- Charleston
- Memphis
- Austin
- Lake Jackson
- Herndon
- Seattle
- Middleton
Questions about this study
What did researchers investigate?
Researchers studied ABT-089, tracking side effects to assess long-term safety and tolerability in adults with ADHD.
Who is behind this study?
The study sponsor is AbbVie (prior sponsor, Abbott).
Did this study involve medication?
Yes. The study involved medication, including ABT-089.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)